EU approvals of GW's cannabinoid Sativex on track
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals is anticipating regulatory approvals of its cannabis extract CB1 agonist Sativex Oromucosal Spray (nabiximols) in the UK and Spain during the second quarter for the treatment of symptoms of spasticity in multiple sclerosis.